Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
|Articles|May 27, 2022
Daily Medication Pearl: Symbyax (Olanzapine and Fluoxetine Hydrochloride)
Author(s)Saro Arakelians, PharmD
Symbyax combines olanzapine, an atypical antipsychotic, and fluoxetine, a selective serotonin reuptake inhibitor, indicated for acute treatment of depressive episodes associated with bipolar I disorder in adults.
Advertisement
Medication Pearl of the Day: Symbyax (Olanzapine and Fluoxetine Hydrochloride)
Indication: Symbyax combines olanzapine, an atypical antipsychotic, and fluoxetine, a selective serotonin reuptake inhibitor, indicated for acute treatment of depressive episodes associated with bipolar I disorder in adults.
Insights:
- Dosing: Once daily in the evening, generally beginning with 6 mg/25 mg
- Dosage forms: Capsules: 3 mg/25 mg, 6 mg/25 mg, 6 mg/50 mg, 12 mg/25 mg, and 12 mg/50 mg
- Adverse events: Most common adverse reactions (≥5% and at least twice that for placebo) are blurred vision,, disturbance in attention, dry mouth, fatigue, hypersomnia, increased appetite, peripheral edema, sedation, somnolence, tremors, and weight gain.
- Mechanism of action: Although the exact mechanism of SYMBYAX is unknown, it has been proposed that the activation of 3 monoaminergic neural systems (dopamine, norepinephrine, and serotonin, ) are responsible for its enhanced antidepressant effect.
Source:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague and which antibiotics the CDC recommends.
In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.
The gap is not a paperwork inconvenience—it is a cash flow problem with clinical consequences.
A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.
In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
Pharmacists can explain the evidence supporting the intramuscular injection, address specific concerns, and help families understand what is known—and what is not known—about oral vitamin K.
Advertisement
Advertisement